Phase I/II Study of an Anti-CD30 Monoclonal Antibody (MDX-060) in Hodgkin's Lymphoma and Anaplastic Large-Cell Lymphoma

Ansell, Stephen M.; Horwitz, Steven M.; Engert, Andreas; Khan, Khuda Dad; Lin, Thomas S.; Strair, Roger; Keler, Tibor; Graziano, Robert F.; Blanset, Diann; Yellin, Michael; Fischkoff, Steven A.; Assad, Albert; Borchmann, Peter

doi:10.1200/jco.2006.07.8972

Cited by 242 publications

(146 citation statements)

References 24 publications

Supporting

Mentioning

137

Contrasting

Unclassified

Order By: Relevance

“…On the other hand, the overall effectiveness may be improved by patient selection based on CD52 positivity, as around half of patients present a consistent downregulation of this antigen (5,(89)(90)(91)(92). Conversely, CD30 is theoretically an optimal target for therapy owing to its minimal expression on nonmalignant cells, although the unconjugated anti-CD30 agents SGN-30 and MDX-060 demonstrated minimal effects in Hodgkin lymphoma and ALCL (93,94). However, more recently, in order to enhance the antitumor activity, the antitubulin agent monomethyl auristatin E (MMAE) was attached to a CD30-specific mAb by an enzyme-cleavable linker, producing the antibody-drug conjugate brentuximab vedotin (SGN-35) (95).…”

Section: Mabs Directed Against Surface Antigensmentioning

confidence: 99%

New molecular insights into peripheral T cell lymphomas

Pileri

Piccaluga

2012

J. Clin. Invest.

View full text Add to dashboard Cite

Peripheral T cell lymphomas (PTCLs) are heterogeneous neoplasms and represent about 12% of all lymphoid malignancies. They are often regarded as "orphan diseases," a designation that does not reflect their real incidence but rather signifies the difficulties encountered in their classification, diagnosis, and treatment. Here we revise the current understanding of the pathobiological characteristics of the most common nodal PTCLs by focusing on the contribution given by high-throughput technologies and the identification of potential therapeutic targets proposed by translational studies.

show abstract

Section: Mabs Directed Against Surface Antigensmentioning

confidence: 99%

New molecular insights into peripheral T cell lymphomas

Pileri

Piccaluga

2012

J. Clin. Invest.

View full text Add to dashboard Cite

show abstract

“…Based on promising in vitro and in vivo data [62], the drug advanced to clinical testing (Table 1). In heavily pretreated patients with relapsed or refractory CD30+ lymphomas, a multicenter phase I/II trial demonstrated a favorable toxicity profile [64]. Clinical activity was however modest, with objective clinical responses occurring in 4 of 67 HL patients.…”

Section: Unconjugated Anti-cd30 Antibodiesmentioning

confidence: 99%

“…Clinical activity was however modest, with objective clinical responses occurring in 4 of 67 HL patients. Some of these patients were taking steroids concomitantly although this was not felt to contribute to the response [64]. Additional patients had disease stabilization.…”

Section: Unconjugated Anti-cd30 Antibodiesmentioning

confidence: 99%

Immunotherapies for Hodgkin's lymphoma

Kasamon

Ambinder

2008

Critical Reviews in Oncology/Hematology

View full text Add to dashboard Cite

show abstract

“…The antibodies failed to show effi cient antitumor activity (Ansell et al, 2007;Forero-Torres et al, 2009;Blum et al, 2010), but a next-generation drug-antibody conjugate, , improved the modest clinical activity of the unconjugated mAbs. This potent immunotoxin contains the antitubulin agent monomethyl auristatin E attached to SGN-30 (Ofl azoglu et al, 2008).…”

Section: Hrs Cellsmentioning

confidence: 99%

Epstein-Barr Virus-Associated Classical Hodgkin Lymphoma and Its Therapeutic Strategies

Lee¹

2011

Biomolecules and Therapeutics

View full text Add to dashboard Cite

Lymphoma is a type of cancer involving cells of the immune system, and has two major categories: Hodgkin lymphoma (HL) and all other lymphomas (non-HL). Although the two types may display the same symptoms, they are readily distinguishable via microscopic examination, and differ in the way they develop, spread and are treated. HL is a unique clinicopathological disorder characterized by the rare presence of malignant cells (usually accounting for 0.1% to 10% of the cells in the total tumor mass) in a background of a nonneoplastic cellular microenvironment comprising T-and Blymphocytes and other cell types (Weiss et al., 1999). In the United States, about 8,500 new cases of HL were expected to be diagnosed in 2010, and the overall incidence is increasing each year (Maggioncalda et al., 2011).Although the pathogenesis of HL is still largely unknown, the association of HL with Epstein-Barr virus (EBV) infection has been demonstrated in many reports. For examples, HL patients show elevated antibody titers to EBV antigens (Levine et al., 1971), and the risk of developing HL is increased up to three-fold in population that have experienced infectious mononucleosis caused by primary EBV infection (Gutensohn Over the past few decades, our understanding of the epidemiology and immunopathogenesis of Hodgkin lymphoma (HL) has made enormous advances. Consequently, the treatment of HL has changed signifi cantly, rendering this disease of the most curable human cancers. To date, about 80% of patients achieve long-term disease-free survival. However, therapeutic challenges still remain, particularly regarding the salvage strategies for relapsed and refractory disease, which need further identifi cation of better prognostic markers and novel therapeutic schemes. Although the precise molecular mechanism by which Epstein-Barr virus (EBV) contributes to the generation of malignant cells present in HL still remains unknown, current increasing data on the role of EBV in the pathobiology of HL have encouraged people to start developing novel and specifi c therapeutic strategies for EBVassociated HL. This review will provide an overview of therapeutic approaches for acute EBV infection and the classical form of HL (cHL), especially focusing on EBV-associated HL cases. and Cole, 1980), and EBV DNA/RNA can be detected in HL tissues (Brink et al., 1997), suggesting that as a primary event in the development of this disease, EBV infection may play a very crucial role in the pathogenesis of HL. AbstractAccording to a population-based cohort study, the frequency of EBV associated HL among total HL cases varies from 30 to 50% (in certain cases even higher; >90% in developing and underdeveloped countries, and >95% in HIV associated cases), and most of them appear in classical Hodgkin lymphoma (cHL), the major type of HL (Herbst et al., 1991;Pallesen et al., 1991;Ambinder et al., 1993;Leoncini et al., 1996). Since EBV is an oncogenic virus that is able to subvert cellular processes supporting growth and survival, the approach to unravel the f...

show abstract

Phase I/II Study of an Anti-CD30 Monoclonal Antibody (MDX-060) in Hodgkin's Lymphoma and Anaplastic Large-Cell Lymphoma

Abstract: MDX-060 was well tolerated at doses up to 15 mg/kg. MDX-060 has limited activity as a single agent, but the minimal toxicity observed and the significant proportion of patients with stable disease suggests that further study of MDX-060 in combination with other therapies is warranted.

Cited by 242 publications

References 24 publications

New molecular insights into peripheral T cell lymphomas

New molecular insights into peripheral T cell lymphomas

Immunotherapies for Hodgkin's lymphoma

Epstein-Barr Virus-Associated Classical Hodgkin Lymphoma and Its Therapeutic Strategies

Contact Info

Product

Resources

About